23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Alnylam Pharmaceuticals, Inc. › 2025-2026

Alnylam Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Alnylam Pharmaceuticals, Inc.’s Form 8-K, filed May 27, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 714Asset managers, any item
  • 4,710Fund votes
  • May 20, 2026Meeting date

Results at a glance

Meeting of May 20, 2026: 5 items on Alnylam Pharmaceuticals, Inc.’s Form 8-K, filed May 27, 2026: 3 elected · 2 approved.

Dissent

Notable dissent: 1 director (10.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Alnylam Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Alnylam Pharmaceuticals, Inc.

These tallies are Alnylam Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 27, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Alnylam Pharmaceuticals, Inc. — official shareholder meeting results, meeting held May 20, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Stuart A. Arbuckle 115,269,6595,068,46328,296 --5,450,286 96%Elected—
Elect Director: Yvonne L. Greenstreet, M.D. 119,787,307513,04966,062 --5,450,286 99.6%Elected—
Elect Director: Elliott Sigal, M.D., Ph.D. 107,495,42112,844,83626,161 --5,450,286 89%Elected—
2. Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting 111,772,3898,552,53441,495 --5,450,286 93%Approved—
3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 119,847,7355,937,27431,695 --0 95%Approved—

Source: Alnylam Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 27, 2026 — read the filing on EDGAR.

How asset managers voted at the Alnylam Pharmaceuticals, Inc. 2025-2026 meeting

714 asset managers disclosed a vote on at least one Alnylam Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Elliott Sigal, M.D., Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 107,495,421AGAINST: 12,844,836
Details: description as filed, official tally, votes by 155 asset managers

Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D.

Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Elliott Sigal, M.D., Ph.D.”): 107,495,421 for, 12,844,836 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 155 asset managers below reported 68,794,831 for, 5,761,800 against, 9,950 abstained, 112 not voted.

FOR
FOR: 68,794,831AGAINST: 5,761,800ABSTAIN: 9,950NOT VOTED: 112
Largest asset managers voting on “To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D.” at Alnylam Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard14,748,186103 00For
Fidelity13,032,4490 00For
Capital Group12,701,0260 00For
T. Rowe Price04,184,185 00Against
BlackRock4,018,6570 00For
Invesco3,900,8920 00For
JPMorgan3,811,5480 00For
AMCAP FUND3,744,6590 00For
INVESTMENT CO OF AMERICA1,947,7870 00For
Dodge & Cox1,464,0410 00For
American Century1,291,0920 00For
Jackson National408,600610,709 00Mixed
NEW ECONOMY FUND867,3150 00For
Charles Schwab648,6900 00For
Federated Hermes487,2570 00For
Legg Mason397,8840 00For
First Trust377,1100 00For
MFS338,5750 00For
State Street944332,986 00Against
Voya313,7910 00For
TIAA311,1890 00For
CARILLON SERIES TRUST251,9400 00For
FRANKLIN STRATEGIC SERIES235,5930 00For
Equitable193,36638,126 00Mixed
ProShares183,4050 00For

Showing the 25 largest of 155 asset managers. All 155 are in the interactive database (link above).

Elect Director: Stuart A. Arbuckle

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 115,269,659AGAINST: 5,068,463
Details: description as filed, official tally, votes by 155 asset managers

Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Stuart A. Arbuckle

Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Stuart A. Arbuckle”): 115,269,659 for, 5,068,463 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 155 asset managers below reported 70,281,402 for, 4,275,228 against, 9,950 abstained, 112 not voted.

FOR
FOR: 70,281,402AGAINST: 4,275,228ABSTAIN: 9,950NOT VOTED: 112
Largest asset managers voting on “To elect the following nominees as Class I directors of Alnylam: Stuart A. Arbuckle” at Alnylam Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard14,748,24544 00For
Fidelity13,032,4490 00For
Capital Group12,701,0260 00For
T. Rowe Price991,0033,193,182 00Mixed
BlackRock4,018,6570 00For
Invesco3,900,8920 00For
JPMorgan3,811,5480 00For
AMCAP FUND3,744,6590 00For
INVESTMENT CO OF AMERICA1,947,7870 00For
Dodge & Cox1,464,0410 00For
American Century1,291,0920 00For
Jackson National408,600610,709 00Mixed
NEW ECONOMY FUND867,3150 00For
Charles Schwab648,6900 00For
Federated Hermes487,2570 00For
Legg Mason397,8840 00For
First Trust377,1100 00For
MFS338,5750 00For
State Street333,9300 00For
Voya313,7910 00For
TIAA311,1890 00For
CARILLON SERIES TRUST251,9400 00For
FRANKLIN STRATEGIC SERIES235,5930 00For
Equitable231,4920 00For
ProShares183,4050 00For

Showing the 25 largest of 155 asset managers. All 155 are in the interactive database (link above).

Elect Director: Yvonne L. Greenstreet, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 119,787,307AGAINST: 513,049
Details: description as filed, official tally, votes by 155 asset managers

Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Yvonne L. Greenstreet, M.D.

Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Yvonne L. Greenstreet, M.D.”): 119,787,307 for, 513,049 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 155 asset managers below reported 74,494,553 for, 62,075 against, 9,950 abstained, 112 not voted.

FOR
FOR: 74,494,553AGAINST: 62,075ABSTAIN: 9,950NOT VOTED: 112
Largest asset managers voting on “To elect the following nominees as Class I directors of Alnylam: Yvonne L. Greenstreet, M.D.” at Alnylam Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard14,748,2843 00For
Fidelity13,032,4490 00For
Capital Group12,701,0260 00For
T. Rowe Price4,184,1850 00For
BlackRock4,018,6570 00For
Invesco3,900,8920 00For
JPMorgan3,811,5480 00For
AMCAP FUND3,744,6590 00For
INVESTMENT CO OF AMERICA1,947,7870 00For
Dodge & Cox1,464,0410 00For
American Century1,291,0920 00For
Jackson National1,019,3090 00For
NEW ECONOMY FUND867,3150 00For
Charles Schwab648,6900 00For
Federated Hermes487,2570 00For
Legg Mason397,8840 00For
First Trust377,1100 00For
MFS338,5750 00For
State Street333,9300 00For
Voya313,7910 00For
TIAA311,1890 00For
CARILLON SERIES TRUST251,9400 00For
FRANKLIN STRATEGIC SERIES235,5930 00For
Equitable201,36230,130 00Mixed
ProShares183,4050 00For

Showing the 25 largest of 155 asset managers. All 155 are in the interactive database (link above).

2. The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 19 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 111,772,389AGAINST: 8,552,534
Details: description as filed, official tally, votes by 714 asset managers

Description as filed by funds: To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.

Alnylam Pharmaceuticals, Inc.’s own tally for this item (“2. The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting”): 111,772,389 for, 8,552,534 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 150 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at Alnylam Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard14,748,24346 00For
Fidelity13,032,4490 00For
Capital Group12,701,0260 00For
T. Rowe Price3,975,770208,415 00For
BlackRock4,018,6570 00For
Invesco3,392,831508,061 00Mixed
JPMorgan3,811,5480 00For
AMCAP FUND3,744,6590 00For
INVESTMENT CO OF AMERICA1,947,7870 00For
Dodge & Cox1,464,0410 00For
American Century1,291,0920 00For
Jackson National1,019,3090 00For
NEW ECONOMY FUND867,3150 00For
Charles Schwab648,6900 00For
Federated Hermes487,2570 00For
Legg Mason397,8840 00For
First Trust377,1100 00For
MFS338,5750 00For
State Street333,9300 00For
Voya313,7910 00For
TIAA311,1890 00For
CARILLON SERIES TRUST251,9400 00For
FRANKLIN STRATEGIC SERIES235,5930 00For
Equitable231,4920 00For
Lincoln Financial143,40576,650 00Mixed

Fund voting reports, all 150 managers: 73,699,593 for, 843,838 against, 9,950 abstained, 112 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 599 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at Alnylam Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity14,084,9310 00For
Capital Group10,822,2950 00For
Capital Research Global Investors9,449,4280 00For
T. Rowe Price6,282,021310,421 00For
BlackRock5,511,0040 00For
State Street2,779,2863,361 00For
GEODE CAPITAL MANAGEMENT, LLC2,670,1970 00For
Wellington1,852,4210 00For
Dodge & Cox1,815,4280 00For
American Century1,605,5540 00For
Vanguard1,199,0590 00For
Orbis Allan Gray Ltd1,134,0010 00For
Clearbridge Investments, LLC1,113,0210 00For
Invesco85,524835,972 00Mixed
BAILLIE GIFFORD & CO LTD871,9860 00For
BAILLIE GIFFORD OVERSEAS LTD809,4690 00For
Northern Trust752,0820 00For
Charles Schwab737,6610 00For
Two Sigma696,7840 00For
Federated Hermes673,6034,088 00For
DE Shaw602,6740 00For
Amundi0579,094 00Against
Legal & General Investment Management Ltd0558,570 00Against
MARSHALL WACE, LLP556,8810 00For
JPMorgan523,4760 00For

Institutional-manager reports, all 599 managers: 81,439,339 for, 4,809,109 against, 91 abstained, 11,212 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 119,847,735AGAINST: 5,937,274

Prior year: 94.8% for (May 8, 2025 meeting) ▲ 0.5 pts

Details: description as filed, official tally, votes by 155 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2026.

Alnylam Pharmaceuticals, Inc.’s own tally for this item (“3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026”): 119,847,735 for, 5,937,274 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 155 asset managers below reported 73,845,890 for, 710,740 against, 9,950 abstained, 112 not voted.

FOR
FOR: 73,845,890AGAINST: 710,740ABSTAIN: 9,950NOT VOTED: 112
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as ” at Alnylam Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard14,088,432659,857 00For
Fidelity13,032,4490 00For
Capital Group12,701,0260 00For
T. Rowe Price4,184,1850 00For
BlackRock4,018,6570 00For
Invesco3,900,8920 00For
JPMorgan3,811,5480 00For
AMCAP FUND3,744,6590 00For
INVESTMENT CO OF AMERICA1,947,7870 00For
Dodge & Cox1,464,0410 00For
American Century1,291,0920 00For
Jackson National1,019,3090 00For
NEW ECONOMY FUND867,3150 00For
Charles Schwab648,6900 00For
Federated Hermes487,2570 00For
Legg Mason397,8840 00For
First Trust377,1100 00For
MFS338,5750 00For
State Street333,91911 00For
Voya313,7910 00For
TIAA311,1890 00For
CARILLON SERIES TRUST251,9400 00For
FRANKLIN STRATEGIC SERIES235,5930 00For
Equitable231,4920 00For
ProShares183,4050 00For

Showing the 25 largest of 155 asset managers. All 155 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of May 8, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest Alnylam Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 132,376,000 shares outstanding at the time of that meeting.

Fund voting reports: top Alnylam Pharmaceuticals, Inc. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 11.14%
2Fidelity 9.85%
3Capital Group 9.59%
4T. Rowe Price 3.16%
5BlackRock 3.04%
6Invesco 2.95%
7JPMorgan 2.88%
8AMCAP FUND 2.83%
9INVESTMENT CO OF AMERICA 1.47%
10Dodge & Cox 1.11%
Institutional-manager reports: top Alnylam Pharmaceuticals, Inc. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 10.64%
2Capital Group 8.18%
3Capital Research Global Investors 7.14%
4T. Rowe Price 4.98%
5BlackRock 4.16%
6State Street 2.10%
7GEODE CAPITAL MANAGEMENT, LLC 2.02%
8Wellington 1.40%
9Dodge & Cox 1.37%
10American Century 1.21%

Reported Alnylam Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Alnylam Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)14,579,166 11.01%Form 13F, quarter ended March 31, 2026
Capital World Investors10,916,799 8.25%Schedule 13G, filed May 14, 2026
BlackRock10,444,908 7.89%Form 13F, quarter ended March 31, 2026
Capital Research Global Investors9,471,181 7.15%Schedule 13G, filed May 14, 2026
JPMorgan Chase6,323,752 4.78%Form 13F, quarter ended March 31, 2026
State Street3,322,698 2.51%Form 13F, quarter ended March 31, 2026
Two Sigma1,992,577 1.51%Form 13F, quarter ended March 31, 2026
Wellington Management1,935,925 1.46%Form 13F, quarter ended March 31, 2026
D.E. Shaw1,474,362 1.11%Form 13F, quarter ended March 31, 2026
T. Rowe Price1,432,748 1.08%Form 13F, quarter ended March 31, 2026

Percentages above are of 132,376,000 shares outstanding, as reported by Alnylam Pharmaceuticals, Inc. on its Form 10-K dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Alnylam Pharmaceuticals, Inc.'s shareholder meeting held May 20, 2026, in the 2025-2026 proxy season, 714 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 4,710 separate fund positions. On the most widely held item on that ballot — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — Alnylam Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Alnylam Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 27, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Alnylam Pharmaceuticals, Inc.’s 10-K dated December 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Alnylam Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Alnylam Pharmaceuticals (ALNY) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/alnylam-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.